The disclosure provides a selective inhibitor of DNA-binding to poly (ADP-ribose) polymerase 1 (PARP1), or a pharmaceutically acceptable salt or solvate thereof, for use in treating, ameliorating or preventing cancer. The treatment may be given to a subject suffering from or at risk of osteoporosis or a subject requiring a long-term therapy.

The present invention provides a novel class of dithiocarbamate-metal complexes and their uses in medicine. Also provided by the invention are combinations and pharmaceutical compositions, comprising a dithiocarbamate (or thiuram disulphide) such as disulfiram and cyclodextrin, with a source of a heavy metal. Surprisingly, the inventors found a synergistic potentiation of the anti-tumor effect, when a dithiocarbamate/heavy metal mixture was combined with a cyclodextrin. The compounds and combination of the invention are particularly useful in the treatment of tumor diseases, and other disorders. Provided are the compounds, combination, pharmaceutical compositions and kits, as well as methods for the preparation of the combinations of the invention.

The present invention provides a novel class of dithiocarbamate-metal complexes and their uses in medicine. Also provided by the invention are combinations and pharmaceutical compositions, comprising a dithiocarbamate (or thiuram disulphide) such as disulfiram and cyclodextrin, with a source of a heavy metal. Surprisingly, the inventors found a synergistic potentiation of the anti-tumor effect, when a dithiocarbamate/heavy metal mixture was combined with a cyclodextrin. The compounds and combination of the invention are particularly useful in the treatment of tumor diseases, and other disorders. Provided are the compounds, combination, pharmaceutical compositions and kits, as well as methods for the preparation of the combinations of the invention.

A device for protecting neurons and reducing inflammation and adhesion formation following surgery is provided. Also provided is a method for protecting neurons and reducing inflammation and adhesion formation following surgery. The device includes a bioabsorbale substrate and a layer of an oxidation inhibitor mimicking the effects of superoxide dismutase and catalase enzymes located on a surface of the substrate. Oxidation inhibitors that may be used include EUK-8, EUK-134, EUK-189, and EUK-207 (a mimetic of superoxide dismutase/catalase), monosodium luminol or phenyl N-t-butylnitrone or an analog with similar anti-oxidant properties. The oxidation inhibitors reduce oxidative stress and trigger the subject's natural anti-oxidant and anti-inflammatory defenses, thereby reducing neuron death, loss of neuron connectivity, inflammation and scarring and restoring excitatory function of neurons.

The present disclosure provides method of detecting senescent cells in a cell sample and methods of treating a disease, disorder, or condition associated with senescence in a subject by administering at least one senolytic agent to the subject.

The present disclosure generally relates to the medical use of compositions comprising a mineral salt and a sulfonic acid for prevention and/or treatment of one or more mucosal diseases, disorders, or conditions or one or more dermal diseases, disorders, or conditions.

To develop a compound which is highly accumulated in cancer cells and capable of emitting an -ray and provide a pharmaceutical composition for cancer treatment including the compound.

A pharmaceutical composition for cancer treatment including a compound having a structure in which .sup.211At is introduced as a substituent into an amino acid derivative having an affinity with an amino acid transporter LAT1 or a pharmaceutically acceptable salt of the compound.

The present invention relates to a method for combined administration of carbon monoxide (CO) to an ex-vivo fluid and monitoring of the carbon monoxide administration, said method comprising: (i) generating CO by reacting a CO releasing molecule (CORM) with a release triggering molecule; (ii) administering CO to an ex-vivo fluid by contacting the ex-vivo fluid with the CO generated in step (i) via a gas-permeable membrane; (iii) analyzing carbon monoxide and/or a carbon monoxide marker after administering in step (ii) CO to the ex-vivo fluid by complementary monitoring techniques; (iv) adjusting the CO administration based on the analysis of the carbon monoxide or the carbon monoxide marker carried out in step (iii), if necessary. It furthermore relates to an extracorporeal circuit system for use in the method of the invention.

The present invention relates to a method for combined administration of carbon monoxide (CO) to an ex-vivo fluid and monitoring of the carbon monoxide administration, said method comprising: (i) generating CO by reacting a CO releasing molecule (CORM) with a release triggering molecule; (ii) administering CO to an ex-vivo fluid by contacting the ex-vivo fluid with the CO generated in step (i) via a gas-permeable membrane; (iii) analyzing carbon monoxide and/or a carbon monoxide marker after administering in step (ii) CO to the ex-vivo fluid by complementary monitoring techniques; (iv) adjusting the CO administration based on the analysis of the carbon monoxide or the carbon monoxide marker carried out in step (iii), if necessary. It furthermore relates to an extracorporeal circuit system for use in the method of the invention.

A composition comprises an anti-nucleolin agent conjugated to nanoparticles, and optionally containing gadolinium. Furthermore, a pharmaceutical composition for treating cancer comprises a composition including an anti-nucleolin agent conjugated to nanoparticles, and a pharmaceutically acceptable carrier. The composition enhances the effectiveness of radiation therapy, enhancing contrast in X-ray imaging techniques, and when gadolinium is present, provide cancer selective MRI contrast agents.